EDITORIAL
Published on 22 Jun 2023
Editorial: Concomitant pathogenic mutations in oncogene-driven subgroups: when next generation biology meets targeted therapy in NSCLC
doi 10.3389/fonc.2023.1239304
- 569 views
- 1 citation
- Frontiers in Oncology
- Thoracic Oncology
- Research Topics
- Concomitant Pathogenic Mutations in Oncogene-Driven Subgroups: When Next Generation Biology Meets Targeted Therapy in NSCLC
Concomitant Pathogenic Mutations in Oncogene-Driven Subgroups: When Next Generation Biology Meets Targeted Therapy in NSCLC
4,357
Total downloads
15k
Total views and downloads
Submit your idea
You will be redirected to our submission process.
Articles
ORIGINAL RESEARCH
Published on 20 Sep 2022
Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
doi 10.3389/fonc.2022.1010311
- 5,166 views
- 8 citations
ORIGINAL RESEARCH
Published on 02 Sep 2022
Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
doi 10.3389/fonc.2022.949304
- 3,463 views
- 9 citations
ORIGINAL RESEARCH
Published on 22 Jun 2022
Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
doi 10.3389/fonc.2022.911303
- 2,022 views
- 7 citations
ORIGINAL RESEARCH
Published on 20 May 2022
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma
doi 10.3389/fonc.2022.873111
- 2,121 views
- 5 citations
Published in
Frontiers in Oncology
- Thoracic Oncology
Impact
- 15kTopic views
- 10kArticle views
- 4,357Article downloads